<DOC>
	<DOCNO>NCT00683696</DOCNO>
	<brief_summary>The EchoCRT trial evaluate effect Cardiac Resynchronization Therapy ( CRT ) mortality morbidity subject heart failure due leave ventricular systolic dysfunction , already receive optimize HF medication , narrow QRS width ( &lt; 130 m ) echocardiographic evidence ventricular dyssynchrony .</brief_summary>
	<brief_title>Echocardiography Guided Cardiac Resynchronization Therapy ( EchoCRT )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Men woman 18 year age old . Understand nature procedure . Give write informed consent . Willing able complete testing require clinical protocol . Indication implantable cardioverter defibrillator ( ICD ) . NYHA class IIIIV within last three month prior enrollment baseline ( baseline : also Stage C accord ACC/AHA guideline ) . Stable optimal pharmacologic therapy HF . An ejection fraction ≤ 35 % within one year prior enrollment confirm baseline echocardiogram . Increased leave ventricular dimension , define LVEDD ≥ 55 mm . Resting QRS duration &lt; 130 m evidence historical 12lead ECG prior enrollment baseline . Ventricular dyssynchrony assess echocardiography locally confirm echo core lab . One two follow criterion present include subject study : Intraleft ventricular dyssynchrony measure color Tissue Doppler Imaging ( TDI ) oppose wall delay ≥ 80 m 4chamber apical longaxis view . Speckletracking radial strain septalposterior wall delay ≥ 130 ms. Implanted pacemaker defibrillator &gt; 10 % ventricular pacing , demonstrate device statistic average least last three month prior enrollment . Women pregnant , lactating , plan become pregnant course trial . Bradycardia pace indication . Surgically correctable primary valvular heart disease , i.e . aortic stenosis , torn cordae , flail segment . Coronary artery bypass graft surgery percutaneous coronary intervention ( balloon and/or stent angioplasty ) within past 3 month prior enrollment . Enzymepositive myocardial infarction within past 3 month prior enrollment . Angiographic evidence coronary disease , candidate coronary revascularization likely undergo coronary artery bypass graft surgery percutaneous coronary intervention next 3 month . Irreversible brain damage preexist cerebral disease . Reversible nonischemic cardiomyopathy acute viral myocarditis . Permanent second third degree heart block . Chagas disease . Persistent paroxysmal atrial fibrillation within one month prior enrollment . Expected receive heart transplantation within six month . Current inotropic therapy . Acutely decompensated heart failure . Contrast dye allergy unable unwilling undergo pretreatment steroid and/or diphenhydramine . Life expectancy less six month . Presence disease , subject 's cardiac disease associate reduce likelihood survival duration trial , ( e.g . cancer ) . Significant renal insufficiency define serum creatinine &gt; 2.5 mg/dL ( &gt; 221 µmol/L ) within last four week prior enrollment.. Liver failure , define three time upper limit normal aminotransferase . Participation clinical trial . Unable return followup visit due distance clinic . Do anticipate resident area schedule duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dyssynchrony</keyword>
	<keyword>Mechanical Dyssynchrony</keyword>
	<keyword>Intraventricular Dyssynchrony</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Normal QRS</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>EchoCRT</keyword>
</DOC>